HomeB1NT34 • BVMF
add
Biontech Se Bdr
Previous close
R$31.72
Day range
R$30.80 - R$32.00
Year range
R$26.80 - R$49.05
Market cap
20.83B USD
Avg Volume
473.00
In the news
Financials
Income Statement
Revenue
Net income
| (EUR) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 1.19B | -19.54% |
Operating expense | 788.00M | 167.66% |
Net income | 259.50M | -43.33% |
Net profit margin | 21.81 | -29.55% |
Earnings per share | 1.08 | -43.16% |
EBITDA | 278.30M | -73.22% |
Effective tax rate | 13.84% | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 16.78B | 1.42% |
Total assets | 22.53B | -2.07% |
Total liabilities | 3.12B | 12.98% |
Total equity | 19.41B | — |
Shares outstanding | 239.97M | — |
Price to book | 0.39 | — |
Return on assets | 1.76% | — |
Return on capital | 2.03% | — |
Cash Flow
Net change in cash
| (EUR) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 259.50M | -43.33% |
Cash from operations | -463.30M | -154.45% |
Cash from investing | 606.70M | 122.51% |
Cash from financing | -7.30M | 43.41% |
Net change in cash | 137.30M | 107.49% |
Free cash flow | -47.54M | -105.76% |
About
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
CEO
Founded
2008
Website
Employees
6,772
